ReviewCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2005
Modern antipsychotic drugs: a critical overview.
Review in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 2 syntheses or guidelines pooled it, 416 citations in OpenAlex.
- Haloperidol dose for the acute phase of schizophrenia.The Cochrane database of systematic reviews · 2013Pooled it
- D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.The American journal of psychiatry · 2010Pooled it
- Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.Human brain mapping · 2013Trial
- Rodent models and accompanying in vitro strategies for studying the etiology and therapy of Parkinson's disease.Journal of Parkinson's disease · 2026Review
- The Impact of Sex and Age on Antipsychotic Serum Concentrations.Schizophrenia bulletin · 2026Article
- Second-generation antipsychotics - Cardiac ion channel modulation and QT interval disturbances: A review.Biomolecules & biomedicine · 2025Review
- Novel electroencephalographic biomarkers for the prediction of responders to an experimental glutamatergic agent in patients with schizophrenia.Translational psychiatry · 2025Article
- Acute Behavioral and Neurochemical Effects of Sulpiride in Adult Zebrafish.Neurochemical research · 2024Article
- Hyperbaric Oxygen Therapy Ameliorates Olanzapine-Induced Hypolocomotion in a Rat Model.Life (Basel, Switzerland) · 2024Article
- A Review of Drug Abuse, Misuse, and Related Laboratory Challenges.Current drug safety · 2024Review
- Liquid antipsychotics in the management of psychomotor agitation: a focus on promazine.Drugs in context · 2024Review
- Chronic treatment with D2-antagonist haloperidol leads to inhibitory/excitatory imbalance in striatal D1-neurons.Translational psychiatry · 2023Article
- Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions.Translational neurodegeneration · 2023Review
- Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms.Pharmacological reports : PR · 2023Review
- Seventy Years of Antipsychotic Development: A Critical Review.Biomedicines · 2023Review
- Hepatitis B and C in individuals with a history of antipsychotic medication use: A population-based evaluation.PloS one · 2023Article
- Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphisms.Toxicology research · 2022Article
- Drug-induced stuttering: A comprehensive literature review.World journal of psychiatry · 2022Review
- Whose responsibility? Part 2 of 2: views of patients, families, and clinicians about responsibilities for addressing the needs of persons with mental health problems in Chennai, India and Montreal, Canada.International journal of mental health systems · 2022Article
- Whose responsibility? Part 1 of 2: A scale to assess how stakeholders apportion responsibilities for addressing the needs of persons with mental health problems.International journal of mental health systems · 2022Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional antipsychotic drugs, used for a half century to treat a range of major psychiatric disorders, are being replaced in clinical practice by modern "atypical" antipsychotics, including aripiprazole, clozapine, olanzapine, quetiapine, risperidone and ziprasidone among others. As a class, the newer drugs have been promoted as being broadly clinically superior, but the evidence for this is problematic. In this brief critical overview, we consider the pharmacology, therapeutic effectiveness, tolerability, adverse effects and costs of individual modern agents versus older antipsychotic drugs. Because of typically minor differences between agents in clinical effectiveness and tolerability, and because of growing concerns about potential adverse long-term health consequences of some modern agents, it is reasonable to consider both older and newer drugs for clinical use, and it is important to inform patients of relative benefits, risks and costs of specific choices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.